High Risk of Under-Grading and -Staging in Prostate Cancer Patients Eligible for Active Surveillance

Isabel Heidegger¹, Viktor Skradski¹, Eberhard Steiner¹, Helmut Klocker¹, Renate Pichler¹, Andreas Pircher², Wolfgang Horninger¹, Jasmin Bektic¹*

¹ Medical University of Innsbruck, Department of Urology, Innsbruck, Austria, ² Medical University of Innsbruck, Department of Haematology and Oncology, Innsbruck, Austria

* Jasmin.bektic@uki.at

Abstract

Background

Active surveillance (AS) is increasingly offered to patients with low risk prostate cancer. The present study was conducted to evaluate the risk of tumor under-grading and -staging for AS eligibility. Moreover, we analyzed possible biomarkers for predicting more unfavorable final tumor histology.

Methods

197 patients who underwent radical prostatectomy (RPE) but would have met the EAU (European Association of Urology) criteria for AS (PSA < 10 ng/ml, biopsy GS ≤ 6, ≤2 cancer-positive biopsy cores with ≤50% of tumor in any core and clinical stage ≤ T2a) were included in the study. These AS inclusion parameters were correlated to the final histology of the RPE specimens. The impact of preoperative PSA level (low PSA < 4 ng/ml vs. intermediate PSA of > 4–10 ng/ml), PSA density (<15 vs. ≥ 15 ng/ml) and the number of positive biopsy cores (1 vs. 2 positive cores) on predicting upgrading and final adverse histology of the RPE specimens was analyzed in uni- and multivariate analyses. Moreover, clinical courses of undergraded patients were assessed.

Results

In our patient cohort 41.1% were found under-graded in the biopsy (final histology 40.1% GS7, 1% GS8). Preoperative PSA levels, PSA density or the number of positive cores were not predictive for worse final pathological findings including GS >6, extraprostatic extension and positive resection margin (R1) or correlated significantly with up-grading and/or extraprostatic extension in a multivariate model. Only R1 resections were predictable by combining intermediate PSA levels with two positive biopsy cores (p = 0.004). Sub-analyses showed that the number of biopsy cores (10 vs. 15 biopsy cores) had no influence on above mentioned results on predicting biopsy undergrading. Clinical courses of patients showed
that 19.9% of patients had a biochemical relapse after RPE, among all of them were under-graded in the initial biopsy.

**Conclusion**

In summary, this study shows that a multitude of patients fulfilling the criteria for AS are under-diagnosed. The use of preoperative PSA levels, PSA density and the number of positive cores were not predictable for undergrading in the present patient collective.

**Introduction**

Prostate cancer (PCa) is the most common cancer and the second cause of cancer death among men in European countries [1]. In general, PCa is a highly heterogeneous disease, ranging from slow-growing indolent tumors to rapidly progressing highly aggressive carcinomas associated with significant morbidity and mortality. Therefore, early detection of PCa by measuring prostate specific antigen (PSA) values at regular intervals in peripheral blood is important to identify men with aggressive cancers at early stage [2].

Generally, organ confined PCa can be cured either by radical prostatectomy (RPE) or primary radiation therapy. However, in the recent years active surveillance (AS) is promoted as an approach with the aim to reduce overtreatment of patients with low risk PCa. AS implicates the decision not to treat the patient immediately, but to make a close follow up and to treat patients at pre-defined thresholds that classify progression such as short PSA doubling time and deteriorating Gleason Score (GS) on repeat biopsy [3]. According to the guidelines of the European Society of Urology (EAU) AS can be offered to patients with the lowest risk of cancer progression implicating clinical stage T1-2a, PSA < 10 ng/mL, biopsy GS ≤ 6 (at least 10 biopsy cores), ≤ 2 positive biopsies as well as minimal biopsy core involvement (≤ 50% cancer per biopsy) [4].

In the recent years there is a growing body of evidence to support the safety of AS instead of immediate treatment for low risk cancer. Surgery implicates side effects like urinary incontinence, loss of fertility and potency as well as possible intra- or postoperative complications. Also the use of radiation therapy has been associated with side effects including urinary incontinence, radiation-cystitis or secondary cancerous malignancies.

The aim of AS of early prostate cancer is to individualize therapy by selecting for curative therapy only patients with significant cancers.

Based on early data, demonstrating that men with differentiated PCa have a 20-year PCa-specific survival rate of 80–90% without any therapy [5,6], AS is an option in the management of low-risk PCa patients that aims to reduce the risk of over-treatment. Recent data from the PRIAS study showed a disease-specific survival rate of 100% on AS in a median follow-up of 1.6 years [7]. Another prospective study found that only 5/453 patients developed metastatic disease and died from PCa providing support for an AS approach in favorable low risk PCa [8].

Several studies investigated the impact of several biomarkers for predicting disease progression in patients undergoing AS. An overview about selected studies addressing this issue is shown in Table 1. In addition to these other molecular markers like TMSS-ERG fusions or the use of MRI fusion techniques have been reported [4].

The aim of this study was to evaluate the accuracy of staging and grading at the time of biopsy in patients who met the inclusion criteria for AS according to the EAU guidelines [4]. Moreover, we evaluated PSA and the number of positive cores as prediction markers as well as
the impact of PSA density ($< 0.15$ vs $\geq 0.15$ ng/ml) for unfavorable final tumor histology, including higher GS, extraprostatic extension and positive resection margin.

**Patients and Methods**

**Ethics Statement**

The study has been approved by the ethics committee of the Medical University of Innsbruck (study number AM3174, number of the positive votum of the Ethics: UN3174, AM 3174). Written informed consent was given by participants for their clinical records to be used in this study.

A retrospective analysis of 197 patients who underwent RPE due to biopsy verified GS6 PCa between 1996 and 2009 has been performed. Age adjusted PSA levels in combination with percent-free PSA (fPSA) of less than 18% as well as digital rectal examinations were used as criteria for transrectal ultrasound-guided prostate biopsy [9] (Table 2). To diagnose PCa from 1995 to March 2000, 10 systematic transrectal ultrasound (TRUS) guided prostate biopsy cores were taken in a standard spatial distribution by experienced urologists; from April 2000 to 2009 additional five doppler-enhanced targeted biopsies cores were taken on the basis of age-specific PSA reference ranges by an experienced uroradiologist. When more than one core was taken from the same area of the prostate only one core counted as a positive punch. Grey scale TRUS

| Number of patients, % undergrading | PSA | PSA density | Number of positive biopsy cores | Others | Reference (Pubmed ID) |
|-----------------------------------|-----|-------------|---------------------------------|--------|-----------------------|
| 197, 41.1%                        | -   | -           | -                               | -      | Own study             |
| 67, 44.8%                         | +   | Not assessed| Not assessed                     | -      | 22921697              |
| 274, 34.1%                        | Not assessed | + | Not assessed                     | Age    | 23820059              |
| 241, 23%                          | +   | Not assessed| Not assessed                     | -      | 21419438              |
| 376, 32.7%                        | +   | +           | +                               | Free PSA | 20304433            |
| 135, 30%                          | Not assessed | + | Not assessed                     | -      | 21167525              |
| 60, not assessed                  | Not assessed | + | Not assessed                     | KI67   | 18762814              |
| 2449, 28%                         | +   | Not assessed| +                               | PSA doubling time | 23159452       |
| 4500, 50% (all GS 6 tumors)       | +   | +           | Not assessed                     | Age, >4mm disease on core, palpable tumor | 24071481   |
| 757, 21.5%                        | +   | +           | +                               | -      | 21704447              |

doi:10.1371/journal.pone.0115537.t001

**Table 2. Age adjusted biopsy criteria.**

| Age range (years) | PSA range (ng/ml) |
|-------------------|-------------------|
| 40–49             | 0–1.25            |
| 50–59             | 0–1.75            |
| 60–69             | 0–2.25            |
| 70–75             | 0–3.25            |

doi:10.1371/journal.pone.0115537.t002
was done using a Combison 530MT unit (Kretztechnik, Zipf, Austria) fitted with a biplanar probe operating at a frequency of 10 MHz. No template based perineal biopsies or MRI-fusion biopsies were performed.

Each biopsy core was analyzed by an experienced pathologist at Department of Pathology of Medical University Innsbruck.

All patients met the EAU criteria for AS [4] and underwent either open retropubic (1996–2009) or robot-assisted laparascopic (2001–2009) RPE without lymph node extirpation. Biopsy and RPE specimens were analyzed by an experienced uro-pathologist at the Medical University of Innsbruck, Department of Pathology, Innsbruck, Austria.

The correlation of GS 6 in needle biopsy and corresponding RPE specimen was analyzed. Patients were stratified by preoperative PSA levels into a low (≤4 ng/ml) and an intermediate (>4–10 ng/ml) PSA group. Moreover, patients were stratified according to the number of positive biopsies as well according to PSA density <0.15 or ≥0.15 ng/ml. PSA density was calculated as following: total serum PSA / prostate volume. Additionally, the incidence of extraprostatic extension (≥pT3a) and positive surgical margins (R1) was analyzed.

**Statistics**

Statistical calculations were performed using SPSS for Windows (SPSS, Chicago, Illinois, USA). Chi Quadrat test and Fisher’s test were used for evaluation of differences between groups. Moreover, multivariate analyses and logistic regressions were calculated using SPSS. P-values below 0.05 were considered significant (* p < 0.05).

**Results**

We investigated a cohort of 197 patients who underwent RPE between 1995–2009 and met the EAU criteria for AS including PSA <10 ng/ml, biopsy GS 6 with ≤2 cancer-positive cores and ≤50% of any core involved with tumor, clinical stage ≤T2a [4]. All patients were Caucasians and the median age at biopsy was 60.2 years (range 40.9 to 75.2 years). The median preoperative PSA level was 4.10 ng/ml (range 1.87 ng/ml to 9.9 ng/ml). Patients were stratified according to preoperative PSA levels into a low (≤4 ng/ml, 46.2% of patients) and an intermediate (>4–10 ng/ml, 53.8% of patients) PSA group, according to the number of positive biopsies into a 1 and a 2 positive cores group (60.4% and 39.6%, respectively) as well as according to PSA density (<0.15 vs ≥0.15 ng/ml) (Table 3).

A needle biopsy grade of GS 6 was upgraded in the final RPE histology in 81 patients (41.1%). Final grade GS 7 was found in 79 (40.1%), final grade GS 8 in 2 (1%) patients.
Concerning GS 7 tumors, 72/79 tumors were 3+4 tumors, while 7/79 were diagnosed as 4+3 tumors (Table 4).

We wondered if time from biopsy to RPE has an influence on undergrading. Thus, we compared the average time from biopsy to RPE between undergraded and not-undergraded patients. The mean time from biopsy to RPE was 92.5 days in the not-undergraded group (median: 80.5, SD 79.16), while it was 82.7 days in the undergraded group of patients (median: 74.5, SD 59.74). Statistical analyses revealed that time from biopsy to RPE was not a significant factor for undergrading (p = 0.356).

As many patients eligible to AS were upgraded in the final histology, we aimed to identify predictive factors for upgrading. First, we evaluated the number of positive biopsy cores and found no significant correlation between number of positive cores and under-grading in the biopsy (p = 0.568). In line with these findings, the number of positive biopsy cores was not able to predict extraprostatic extension (≤ pT2c vs. ≥pT3a: p = 0.208) or positive surgical margin (p = 0.033).

Next we evaluated the impact of preoperative PSA level on final histology upgrading and found no significant impact (p = 0.116). Also extra-prostatic extension (p = 0.248) and positive surgical margins (p = 0.031) in the RPE specimen were not predictable by preoperative PSA levels.

Moreover, we investigated the impact of PSA density as prediction marker for adverse pathological findings. In line with the number of positive cores and preoperative PSA levels PSA density was not able to predict upgrading (p = 0.718) or extraprostatic extension (p = 0.186). However, the risk for positive surgical margins was significantly predictable by PSA density ≥ 15 ng/ml (p = 0.000).

Employing multivariate analysis we tested the combination of preoperative PSA level, the number of positive biopsy cores and PSA density for predicting an unfavorable final pathology. In line with univariate analyses most combinations of parameters were not able to predict final worse pathological findings including higher GS and extra-prostatic extension (Table 5).

| Table 4. Final GS grade and pathological tumor stage of RPE specimen Statistics: descriptive. |
|--------------------------------------|-----------------|
| Gleason Score RPE                    | n (%)           |
| Gleason Score 5                      | 34 (17.3%)      |
| Gleason Score 6                      | 82 (41.6%)      |
| Gleason Score 7 total                | 79 (40.1%)      |
| Gleason Score 7 3+4                  | 72 (36.6%)      |
| Gleason Score 7 4+3                  | 7 (3.5%)        |
| Gleason Score 8                      | 2 (1%)          |
| pT stadium RPE                       | n (%)           |
| pT2a                                 | 45 (22.8%)      |
| pT2b                                 | 11 (5.6%)       |
| pT2c                                 | 128 (65%)       |
| pT3a                                 | 11 (5.6%)       |
| pT4                                  | 2 (1%)          |
| Surgical margin                      | n (%)           |
| ≤pT2c R0                             | 157 (79.7%)     |
| ≤pT2c R1                             | 27 (13.7%)      |
| ≥pT3a R0                             | 6 (3.0%)        |
| ≤pT3a R1                             | 7 (3.6%)        |

doi:10.1371/journal.pone.0115537.t004
Interestingly, only the combinations of intermediate PSA level + only one positive biopsy core as well as PSA density ≥ 15 ng/ml + intermediate PSA + one positive biopsy core were associated with significant higher number of pT3a tumors (Table 5). Concerning the prediction of both, pT3a tumors and undergrading only the combination PSA density ≥ 15 ng/ml + intermediate PSA + one positive biopsy core was predictive (Table 5).

Positive resection margins were predictable by four different combinations of parameters with the highest impact by combining PSA density ≥ 15 ng/ml/ intermediate PSA and two biopsy cores (p = 0.000) (Table 5). However, logistic regression confirmed no improvement of prediction of PCa aggressiveness by preoperative PSA value, by the number of positive biopsy cores, by PSA density or by combination of these parameters (Table 6).

### Table 5. Multivariate model; PSA levels (ng/ml) the number of positive biopsy cores and PSA density (ng/ml) for predicting worse final pathological findings; Statistics: * Chi-Quadrat Pearson; ** Fisher test.

| Category                        | Undergrading | pT2c versus pT3a | R1            | pT3a+undergrading |
|---------------------------------|--------------|------------------|---------------|------------------|
| PSA ≤4+1 core                   | 0.272*       | 0.274**          | 0.265*        | 0.266**          | 0.418*        |
| PSA >4–10+1 core                | 0.638*       | 0.639**          | 0.016*        | 0.015** (sig)    | 0.776*        |
| PSA ≤4+2 cores                  | 0.448*       | 0.449**          | 0.853*        | 0.854**          | 0.665*        |
| PSA >4–10+2 cores               | 0.174*       | 0.175**          | 0.190*        | 0.191**          | 0.004*        |
| Density <0.15+PSA ≤4+1 core     | 0.300*       | 0.302**          | 0.450*        | 0.452**          | 0.038*        |
| Density ≤0.15+PSA >4–10+1 core  | 0.464*       | 0.465**          | 0.504*        | 0.506**          | 0.272*        |
| Density >0.15+PSA ≤4+2 cores    | 0.795*       | 0.796**          | 0.903*        | 0.904**          | 0.906*        |
| Density >0.15+PSA >4–10+2 cores | 0.141*       | 0.142**          | 0.861*        | 0.861**          | 0.139*        |
| Density >0.15+PSA ≤4+1 core     | 0.821*       | 0.821**          | 0.715*        | 0.716**          | 0.222*        |
| Density >0.15+PSA >4–10+1 core  | 0.985*       | 0.985**          | 0.003* (sig)  | 0.003** (sig)    | 0.792*        |
| Density >0.15+PSA ≤4+2 cores    | 0.392*       | 0.393**          | 0.797*        | 0.797**          | 0.645*        |
| Density >0.15+PSA >4–10+2 cores | 0.690*       | 0.691**          | 0.210*        | 0.212**          | 0.000*        |

### Table 6. Logistic regression for predicting PCa aggressiveness.

| Variables for testing                  | AUC  |
|---------------------------------------|------|
| 1 vs. 2 positive biopsy cores         | 0.520|
| PSA ≤4 vs. PSA 4–10                    | 0.557|
| Density <0.15 vs. ≥0.15                | 0.512|
| PSA ≤4 + 1 positive biopsy core       | 0.464|
| PSA 4–10 + 1 positive biopsy core     | 0.479|
| PSA ≤4 + 2 positive biopsy cores      | 0.516|
| PSA 4–10 + 2 positive biopsy cores    | 0.541|
| Density >0.15 + PSA ≤4 + 1 core       | 0.465|
| Density >0.15 + PSA >4–10 + 1 core    | 0.521|
| Density >0.15 + PSA ≤4 + 2 cores      | 0.493|
| Density >0.15 + PSA >4–10 + 2 cores   | 0.534|
| Density >0.15 + PSA ≤4 + 1 core       | 0.502|
| Density >0.15 + PSA >4–10 + 1 core    | 0.501|
| Density >0.15 + PSA ≤4 + 2 cores      | 0.495|
| Density >0.15 + PSA >4–10 + 2 cores   | 0.490|

Statistics: Logistic regression (AUC), PSA (ng/ml), PSA density (ng/ml).
Moreover, we performed sub-analyses of differences in biopsy techniques 10 cores vs. 15 cores. Thereby we found that undergrading was higher in the group of 15 biopsy cores (44.5%) vs. 19.2% in the group of 10 cores. However, it has to be considered that the number of patients within the groups highly differs (n = 26 vs. n = 171) (Table 7). Final GS of RPE specimens (10 vs. 15 cores) are shown in Table 8. Multivariate analyses revealed that in both groups neither PSA levels, the number of positive cores nor PSA density (in all combinations) were able to predict undergrading (Table 9–10). Also AUC curves did not differ significantly between 10 and 15 biopsy cores (Table 11).

At last we analyzed those patients who were biopsy undergraded. Thereby we found that in our patient collective the incidence of biochemical relapse treated by radiation therapy (72Gy)...

**Table 7. Patient characteristics sub-analyzed according to biopsy cores (10 cores versus 15 cores), Statistics: descriptive.**

| PSA category (ng/ml) | n (%) 10 cores | n (%) 15 cores |
|---------------------|---------------|---------------|
| Total               | 26 (13.2%)    | 171 (66.8%)   |
| PSA ≤4              | 13 (50%)      | 78 (45.6%)    |
| PSA 4–10            | 13(50%)       | 93 (54.4%)    |
| Positive cores category | n (%) | n (%) |
| 1 core              | 15(57.7%)     | 104 (60.8%)   |
| 2 cores             | 11 (42.3%)    | 67 (39.2%)    |
| PSA density (ng/ml) | n (%)         | n (%)         |
| <0.15               | 13 (50%)      | 115(67.3%)    |
| ≥0.15               | 3 (11.5%)     | 47 (27.5%)    |
| Missing             | 10 (38.5%)    | 9 (5.2%)      |

doi:10.1371/journal.pone.0115537.t007

**Table 8. Final GS grade and pathological tumor stage of RPE specimen sub-analyzed according to biopsy cores (10 cores versus 15 cores), Statistics: descriptive.**

| Gleason Score RPE | n (%) 10 cores | n (%) 15 cores |
|-------------------|---------------|---------------|
| Total             | 26 (13.2%)    | 171 (66.8%)   |
| Gleason Score 5   | 7 (26.9%)     | 27 (15.8%)    |
| Gleason Score 6   | 14 (53.8 %)   | 68 (39.8%)    |
| Gleason Score 7 total | 5 (19.2%) | 74 (43.3%)   |
| Gleason Score 7 3+4 | 1 (3.8%) | 68 (39.8%)   |
| Gleason Score 7 4+3 | 1 (3.8%) | 6 (3.5%)     |
| Gleason Score 8   | 0 (0%)        | 2 (1.2%)      |
| pT stadium RPE    | n (%)         | n (%)         |
| pT2a               | 5 (19.2%)     | 40 (23.4%)    |
| pT2b               | 6 (23.1%)     | 5 (2.9%)      |
| pT2c               | 13 (50%)      | 115 (67.3%)   |
| pT3a               | 1 (3.8%)      | 10 (5.8%)     |
| pT4                | 1 (3.8%)      | 1 (0.6%)      |
| Surgical margin   | n (%)         | n (%)         |
| ≤pT2c R0           | 21 (80.8%)    | 136 (79%)     |
| ≤pT2c R1           | 3 (11.5%)     | 24 (14%)      |
| ≥pT3a R0           | 1 (3.8%)      | 5 (2.9%)      |
| ≤pT3a R1           | 1 (3.8%)      | 6 (3.5%)      |

doi:10.1371/journal.pone.0115537.t008
after RPE was 19.2% (n = 8), while only 2.7% (n = 2) were treated hormonally (Fig. 1). Interestingly, all 8 patients, who had a biochemical relapse after RPE, were undergraded in the initial biopsy. Among these, 7 patients had a GS7 in the RPE specimen and 1 patient showed a GS8 in the RPE specimen. Both patients with hormonal treatment were undergraded in the biopsy.

**Discussion**

Many prostate tumors, especially in elderly men, are estimated to have a protracted natural history. However, the majority of men diagnosed with PCa undergo aggressive treatment regardless of risk and changing landscape of PCa. Consequently, a considerable part of PCa is overtreated. For these patients AS could represent an adequate treatment option [10,11].

### Table 9. Multivariate model.

| Category                          | Undergrading | pT2c versus pT3a | R1      | pT3a+ undergrading |
|-----------------------------------|--------------|------------------|---------|-------------------|
| PSA ≤4+ 1 core                    | 0.689        | 0.372            | 0.925   | 0.536             |
| PSA >4–10+1 core                  | 0.619        | 0.540            | 0.036 (sig) | 0.497 |
| PSA ≤4+2 cores                    | 0.856        | 0.347            | 0.234   | 0.630             |
| PSA >4–10+2 cores                 | 0.961        | 0.473            | 0.289   | 0.691             |
| Density <0.15+PSA ≤4+1 core       | 0.182        | 0.551            | 0.712   | 0.551             |
| Density <0.15+PSA >4–10+1 core    | 0.712        | 0.620            | 0.356   | 0.420             |
| Density <0.15+PSA ≤4+2 cores      | 0.712        | 0.032 (sig)      | 0.356   | 0.032 (sig)       |
| Density <0.15+PSA >4–10+2 cores   | 0.961        | 0.473            | 0.289   | 0.691             |
| Density <0.15+PSA ≤4+1 core       | No data      | No data          | No data | No data           |
| Density <0.15+PSA >4–10+1 core    | 0.383        | 0.696            | 0.002 (sig) | 0.696 |
| Density ≥0.15+PSA ≤4+2 cores      | No data      | No data          | No data | No data           |
| Density ≥0.15+PSA >4–10+2 cores   | 0.551        | 0.790            | 0.620   | 0.790             |

PSA levels (ng/ml) the number of positive biopsy cores and PSA density (ng/ml) for predicting worse final pathological findings in the population of 10 biopsy cores, Statistics: Chi-Quadrat Pearson test.

doi:10.1371/journal.pone.0115537.t009

### Table 10. Multivariate model.

| Category                          | Undergrading | pT2c versus pT3a | R1      | pT3a+ undergrading |
|-----------------------------------|--------------|------------------|---------|-------------------|
| PSA ≤4+ 1 core                    | 0.276        | 0.405            | 0.035 (sig) | 0.508 |
| PSA >4–10+1 core                  | 0.741        | 0.018 (sig)      | 0.285   | 0.046 (sig)       |
| PSA ≤4+2 cores                    | 0.548        | 0.500            | 0.962   | 0.575             |
| PSA >4–10+2 cores                 | 0.179        | 0.262            | 0.001 (sig) | 0.320 |
| Density <0.15+PSA ≤4+1 core       | 0.448        | 0.543            | 0.023 (sig) | 0.673 |
| Density <0.15+PSA >4–10+1 core    | 0.489        | 0.591            | 0.853   | 0.678             |
| Density <0.15+PSA ≤4+2 cores      | 0.734        | 0.559            | 0.398   | 0.645             |
| Density <0.15+PSA >4–10+2 cores   | 0.113        | 0.989            | 0.219   | 0.898             |
| Density ≥0.15+PSA ≤4+1+1 core     | 0.859        | 0.715            | 0.218   | 0.730             |
| Density ≥0.15+PSA >4–10+1 core    | 0.817        | 0.001 (sig)      | 0.647   | 0.010 (sig)       |
| Density ≥0.15+PSA ≤4+2 cores      | 0.376        | 0.797            | 0.502   | 0.808             |
| Density ≥0.15+PSA >4–10+2 cores   | 0.713        | 0.221            | 0.000 (sig) | 0.247 |

PSA levels (ng/ml) the number of positive biopsy cores and PSA density (ng/ml) for predicting worse final pathological findings in the population of 15 biopsy cores, Statistics: Chi-Quadrat Pearson test

doi:10.1371/journal.pone.0115537.t010
The present study was undertaken to evaluate the risk of under-grading and -staging when applying the criteria for eligibility for AS. Evaluating 197 patients we found that 41.1% of patients were under-graded. Thus, a large number of patients initially eligible for AS would not meet the AS criteria based on final histology. This finding is in line with a small study involving 67 patients that also found a significant under-estimation of GS in the biopsy compared to the corresponding RPE specimen [12]. Several other studies showed that the needle biopsy GS relates only in about 60 to 75% accurately with the RPE GS [13,14]. Recently, our group described that 52.4% of patients were under-graded in the biopsy [15].

The GS determined in the prostate needle biopsy is an essential component in the algorithm for treatment selection. An under-grading rate of 41.1% found in the present study underscores the risk and consequence of undergrading at biopsy in a group of patients that would have been eligible for conservative management. Thus it seems important to inform patients about the risk of under-grading when considering AS in low risk PCa.

Several studies have been conducted or are ongoing to define predictive factors or methods to improve precise staging of PCa: Fleshner et al for example used repeat biopsies as strategy to improve the reliability of needle biopsy grading in patients with well differentiated PCa (n = 165) [16]. However, repeated biopsies harbor an increased risk of perioperative complications including bleeding complication or febrile prostatitis. Recently, Ehdaie et al for example found that in men with PCa on AS the number of previous prostate biopsies is associated with a significant risk of infectious complications (n = 403) [17]. Han et al described low preoperative PSA as predictor for insignificant PCa (n = 67) [12]. In contrast to this finding, our study indicates that preoperative PSA levels cannot predict biopsy under-grading. Moreover, our study clearly shows that also the number of positive biopsy cores as well as the combination of both factors is not able to predict worse final pathological findings. Again, this finding is in contrast to a large study including 757 patients that found the number of positive cores (two vs. one positive core) at initial biopsy to be predictive for reclassification of PCa one year later [18]. Possible explanations for the different findings in our study may be the fact, that most studies that described PSA as predictor for undergrading involved a larger patient collective. Therefore

| Table 11. Logistic regression for predicting PCa aggressiveness sub-analyzed 10 versus 15 biopsy cores; PSA (ng/ml), PSA density (ng/ml), Statistics: Logistic regression (AUC). |
|-----------------------------------------------|
| Variables for testing                         | 10 cores AUC | 15 cores AUC |
| 1 vs. 2 positive biopsy cores                | 0.542        | 0.512        |
| PSA ≤4 vs. PSA 4–10                          | 0.625        | 0.541        |
| Density <0.15 vs. ≥0.15                      | 0.458        | 0.520        |
| PSA ≤4 + 1 positive biopsy core              | 0.333        | 0.474        |
| PSA 4–10 + 1 positive biopsy core            | 0.625        | 0.514        |
| PSA ≤4 + 2 positive biopsy cores             | 0.542        | 0.484        |
| PSA 4–10 + 2 positive biopsy cores           | 0.500        | 0.528        |
| Density <0.15 + PSA ≤4 + 1 core              | 0.333        | 0.473        |
| Density <0.15 + PSA >4–10 + 1 core           | 0.542        | 0.520        |
| Density <0.15 + PSA ≤4 + 2 cores             | 0.542        | 0.490        |
| Density <0.15 + PSA >4–10 + 2 cores          | 0.542        | 0.537        |
| Density ≥0.15 + PSA ≤4 + 1 core              | 0.500        | 0.502        |
| Density ≥0.15 + PSA >4–10 + 1 core           | 0.583        | 0.493        |
| Density ≥0.15 + PSA ≤4 + 2 cores             | 0.500        | 0.495        |
| Density ≥0.15 + PSA >4–10 + 2 cores          | 0.458        | 0.490        |

doi:10.1371/journal.pone.0115537.t011
one could speculate that the statistical power of this study is too low for make a definitive statement.

Additionally we investigated in this study the impact of PSA density as a possible marker for predicting unfavorable pathological findings. Several studies support the inclusion of PSA density, rather than PSA, into the risk stratification system for patients seeking less invasive treatment for PCa. Oh et al for example found that PSA density may be a significantly more accurate preoperative predictor of upgrading than PSA (n = 505) [19]. Moreover, a recently published population study including 4500 men showed that PSA density ≥0.15 ng/ml is a predictor for adverse pathology (upgrading to GS 7 or higher, or up staging to pT3 or greater) [20]. Our findings are in contrast to these findings where we did not find PSA density ≥0.15 ng/ml as predictor for undergrading or extraprostatic extension. Only positive surgical margins were predictable by PSA density ≥0.15 ng/ml.

For a majority of patients with low risk PCa, AS offers the benefit of personalized medicine, avoiding treatment and possible negative effects on quality-of-life. Several studies addressed the quality-of-life issues in men managed in the AS regime compared to those with RPE. A recent study evaluated the prevalence of depression, anxiety and distress among AS and RPE patients and found no significant difference [21]. However, radical treatment often implicates significant side effects which often have an enormous impact on patients’ quality-of-life that
would be avoided by selecting AS. A recent longitudinal study for example including 374 men showed that men in the RPE group consistently reported more leakage, impaired erection and libido, and fewer obstructive voiding symptoms compared to the watchful waiting group [22].

Clinical courses of patients clearly showed that all patients who had biochemical relapse after RPE were undergraded in the biopsy. This finding indicates that undergrading in patients stratified for AS lead to increased PCa progression. These data illustrate again, that AS regime has to be selected very carefully especially in young men.

Strengths of the present study are the homogenous population due to uniformly applied inclusion criteria and the large patient collective. Another important aspect of our findings is that PCa diagnosis was made through extended biopsy protocols (10–15 biopsies), which is known to improve diagnosis and reduce sampling errors.

A limitation of the study is that we analyzed a highly selected screening population from the Tyrol study. Moreover, it has also to be considered, that the potential under-estimation of GS and tumor extent may also result from sampling bias, variation in biopsy numbers and inter-observer variability among pathologists for grading of PCa. Although all biopsies were taken according to an internal scheme, biopsies were performed by multiple individuals which could be an additional confounding factor in the biopsy outcomes.

**Conclusion**

AS for favorable risk PCa is an approach that may reduce over-treatment of clinically insignificant PCa. However, our results show that 41.1% of patients treated by RPE at our institution who would have met the inclusion criteria for AS, had a worse final histology and therefore would not have been destined for followed-up in an AS strategy. Neither preoperative PSA levels nor the number of positive biopsy cores or PSA density were predicting adverse final pathological findings. Only positive surgical margins were predictable by PSA density \( \geq 0.15 \) ng/ml. Moreover, we found that undergraded patients have a higher risk of PCa progression.

These findings should be considered in the decision process regarding the treatment of patients with localized PCa especially for those with a life expectancy of \( >10 \) years. Therefore it is important to inform the patient about the possibility of under-grading in the prostate biopsy. An unresolved problem remains the lack of accurate markers for definition of significant or insignificant disease and an increased confidence towards conservative treatment of PCa.

**Author Contributions**

Conceived and designed the experiments: IH VS WH JB. Performed the experiments: IH VS RP. Analyzed the data: IH AP ES. Contributed reagents/materials/analysis tools: HK WH. Wrote the paper: IH VS AP ES RP. Supervision: HK WH JB.

**References**

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61: 69–90. doi:10.3322/caac.20107 PMID: 21296855
2. Catalona WJ, Partin AW, Finlay JA, Chan DW, Rittenhouse HG et al (1999) Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when PSA levels are 2.51 to 4 ng/mL and digital rectal examination is not suspicious for prostate cancer: an alternative model. Urology 54: 220–224. PMID: 10443714
3. Klotz L (2012) Active surveillance for low-risk prostate cancer. F1000 Med Rep 4: 16. doi:10.3410/M4-16 PMID: 22891078
4. EAU guidelines on Prostate cancer, www.uroweb.org
5. Chodak GW, Thisted RA, Gerber GS, Johansson JE, Adolfsson J, et al (1994) Results of conservative management of clinically localized prostate cancer. N Engl J Med 330: 242–248. PMID: 8272085
6. Albertsen PC, Hanley JA, Fine J (2005) 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 293: 2095–2101. PMID: 15870412

7. Bul M, Zhu X, Valdagni R, Pickles T, Kakehi Y, et al (2013) Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. Eur Urol 63: 597–603. doi: 10.1016/j.eururo.2012.11.005 PMID: 23159452

8. Krakowsky Y, Loblaw A, Klotz L (2010) Prostate cancer death of men treated with initial active surveillance: clinical and biochemical characteristics. J Urol 184: 131–135. doi: 10.1016/j.juro.2010.03.041 PMID: 20478589

9. Reissigl A, Horninger W, Fink K, Klocker H, Bartsch G (1997) Prostate carcinoma screening in the county of Tyrol, Austria: results and experience. Cancer 80: 1818–1829. PMID: 9351555

10. Graefen M, Schlomm T (2013) Active surveillance for low-risk prostate cancer: some questions are answered, but many questions remain. Eur Urol 63: 604–605. doi: 10.1016/j.eururo.2012.12.003 PMID: 23265390

11. Thomsen FB, Roder MA, Hvamnese N, Iversen P, Brasso K (2013) Active surveillance can reduce overtreatment in patients with low-risk prostate cancer. Dan Med J 60: A4575. PMID: 23461989

12. Han JS, Toll AD, Amin A, Carter HB, Landis P, et al (2012) Low prostate-specific antigen and no Gleason score upgrade despite more extensive cancer during active surveillance predicts insignificant prostate cancer at radical prostatectomy. Urology 80: 883–888. doi: 10.1016/j.urology.2012.05.045 PMID: 22921697

13. Oliveira IS, Pontes-Junior J, Abe DK, Crippa A, Dall'oglio MF, et al (2010) Undergrading and understaging in patients with clinically insignificant prostate cancer who underwent radical prostatectomy. Int Braz J Urol 36: 292–299. PMID: 20602821

14. Berg KD, Toft BG, Roder MA, Brasso K, Vainer B, et al (2011) Prostate needle biopsies: interobserver variation and clinical consequences of histopathological re-evaluation. APMIS 119: 239–246. doi: 10.1111/j.1600-0463.2011.02723.x PMID: 21492223

15. Heidegger I, Ladurner M, Skradski V, Klocker H, Schafer G, et al (2012) Adverse Pathological Findings in Needle Biopsy Gleason Score 6 Prostate Cancers with Low and Intermediate Preoperative PSA Levels Following Radical Prostatectomy. Anticancer Res 32: 5481–5485. PMID: 23225455

16. Fleshner NE, Cookson MS, Soloway SM, Fair WR (1998) Repeat transrectal ultrasound-guided prostate biopsy: a strategy to improve the reliability of needle biopsy grading in patients with well-differentiated prostate cancer. Urology 52: 659–662. PMID: 9763089

17. Ehdale B, Vertosick E, Spaliviero M, Giallo-Uvino A, Taur Y, et al (2013) The Impact of Repeat Biopsies on Infectious Complications in Men with Prostate Cancer on Active Surveillance. J Urol.

18. Bul M, van den Bergh RC, Rannikko A, Valdagni R, Pickles T, et al (2012) Predictors of unfavourable repeat biopsy results in men participating in a prospective active surveillance program. Eur Urol 61: 370–377. doi: 10.1016/j.eururo.2011.06.027 PMID: 21704447

19. Oh JJ, Hong SK, Lee JK, Lee BK, Lee S, et al (2012) Prostate-specific antigen vs prostate-specific antigen density as a predictor of upgrading in men diagnosed with Gleason 6 prostate cancer by contemporory multicore prostate biopsy. BJU Int 110: E494–E499. doi: 10.1111/j.1464-410X.2012.11182.x PMID: 22540236

20. Vellekoop A, Loeb S, Folkvaljon Y, Statin P (2014) Population based study of predictors of adverse pathology among candidates for active surveillance with gleason 6 prostate cancer. J Urol 191: 350–357. doi: 10.1016/j.juro.2013.09.034 PMID: 24071481

21. Punnen S, Cowan JE, Dunn LB, Shumay DM, Carroll PR, et al (2013) A longitudinal study of anxiety, depression and distress as predictors of sexual and urinary quality of life in men with prostate cancer. BJU Int 112: E67–E75. doi: 10.1111/bju.12209 PMID: 23795800

22. Bill-Axelson A, Garmo H, Holmberg L, Johansson JE, Adami HO, et al (2013) Long-term Distress After Radical Prostatectomy Versus Watchful Waiting in Prostate Cancer: A Longitudinal Study from the Scandinavian Prostate Cancer Group-4 Randomized Clinical Trial. Eur Urol.